Comprehensive review addresses how GLP-1 agonists are used in everyday clinical practice, covering prescribing patterns, adherence, insurance barriers, and off-label use from a scientific committee perspective.
Trial vs reality gapReal-world GLP-1 drug adherence and outcomes lag behind clinical trials due to access, cost, and implementation barriers
What the researchers found
Real-world GLP-1 drug use faces significant implementation challenges including adherence, insurance barriers, off-label expansion, and prescribing pattern variability versus clinical trials.
Why it matters
Effective drugs only work if patients can access and continue them. Understanding the gap between clinical trial efficacy and real-world effectiveness is essential for improving GLP-1 drug outcomes for the millions who need them.
The numbers in context
Not specified in available abstract — the review covers multiple clinical trials and therapeutic indications.
How the study worked
Scientific committee review of GLP-1 agonist prescribing patterns, adherence data, implementation challenges, and clinical practice optimization strategies.
Who was studied
Broad — patients with diabetes, obesity, cardiovascular disease, and kidney disease
What this study cannot tell us
Implementation challenges vary by healthcare system and country. Solutions that work in one setting may not apply elsewhere. Rapidly evolving insurance and pricing landscape.
How to read the evidence
Moderate evidence: expert scientific committee review with practical guidance based on available real-world data.
When this study was published
Published in 2025. Addresses the current state of GLP-1 implementation challenges.
The bigger picture
The GLP-1 revolution faces a critical implementation phase. Having effective drugs is only half the equation — ensuring patients can access, afford, and continue them determines whether the promising trial data translates into real population health improvement.
Questions still open
- What interventions most improve GLP-1 drug adherence in real-world settings?
- How should insurance coverage criteria for GLP-1 drugs be designed for optimal population benefit?
- Will biosimilar GLP-1 drugs solve access problems?
Common questions
Why is it hard to get GLP-1 drugs in real life?
How can I stay on my GLP-1 drug long-term?
Read the original research
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation.
Current atherosclerosis reports, 27(1), 99
Citation
Abu-Nejim, Husam; Becker, Richard C. (2025). Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation.. Current atherosclerosis reports, 27(1), 99. https://doi.org/10.1007/s11883-025-01350-7